From Yahoo Finance: 2025-05-27 13:59:00

Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (NASDAQ:BCAX) with a price target of $36 after the company released interim data from the Phase 1/1b trial of Ficerafusp alfa, its lead asset and a first-in-class bifunctional antibody.

Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company developing innovative bifunctional antibody therapies for solid tumors, with Ficerafusp alfa aimed at enhanced tumor penetration to overcome immunosuppressive tumor microenvironments in solid tumors.

Promising results from the Phase 1/1b study of Ficerafusp alfa in treating HPV-negative patients with head and neck squamous cell carcinoma include a median overall survival exceeding 20 months and an 18-21% complete response rate, positioning the treatment as a potential breakthrough in challenging therapeutic areas.

While BCAX shows investment potential, some AI stocks may offer higher returns with limited downside risk. For those seeking AI stocks with 100x upside potential, consider exploring the report on the cheapest AI stock for promising opportunities beyond BCAX.

Read more: Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update